


Scientific Programme

XII International Forum for the Evaluation of Cardiovascular Care

*Budapest, March 24-26, 2011
Budapest Congress & World Trade Centre*



European Society of Hypertension



Organizing Secretariat



AIM Group

Rome Office: via Flaminia, 1068 - 00189 Rome (Italy)

Ph. 06 330531 - Fax 06 33053229

ifecc2011@aimgroup.eu

www.aimgroup.eu/2011/ifecc



SCIENTIFIC AND ORGANIZING COMMITTEE

J.M. Mallion (France)

G. Mancia (Italy)

L.M. Ruilope (Spain)

A. Zanchetti (Italy)

SCIENTIFIC AND ORGANIZING SECRETARIAT

AIM Group – AIM CONGRESS
Rome Office – Via Flaminia, 1068 – 00189 Rome, Italy
Tel: +39 06 33053 1
Fax: +39 06 33053 229
E-mail: ifecc2011@aimgroup.eu

UNDER THE AUSPICES OF



European Society of Hypertension



SCIENTIFIC PROGRAMME AND PROPOSED SPEAKERS

The Cardiovascular Patient: Challenges and New Opportunities
Budapest, 24-26 March, 2011

THURSDAY, MARCH 24

15.00 Opening

G. Mancina (Italy) and C. Farsang (Hungary)

Session 1

Resistant hypertension

Chairpersons: J.M. Mallion (France) and J.L. Rodicio (Spain)

15.10 Resistant hypertension - definition and prevalence

A. de la Sierra (Spain)

15.35 Role of aldosterone blockers in resistant hypertension

J. Segura (Spain)

16.00 Renal denervation - a new mechanism to treat resistant hypertension

G. Grassi (Italy)

16.25 Carotid baroreflex stimulation in resistant hypertension

TBD

Session 2

ARBs: going above and beyond the class effect

supported by an unrestricted educational grant of Menarini International

Chairpersons: A. Zanchetti (Italy) and J. Redon (Spain)

16.50 Initial Televoter

17.00 Monotherapy as first approach

M. Burnier (Switzerland)

17.25 Adding hydrochlorothiazide - a well made match

L.C. Rump (Germany)

17.50 Organ protection in hypertension: what we have learned from ROADMAP

H. Haller (Germany)

18.15 The polypill approach: what, why, when and whom?

M. Volpe (Italy)

18.40 Final Televoter

18.50 WELCOME COCKTAIL

FRIDAY, MARCH 25

Session 3

Blood pressure targets in antihypertensive therapy

Chairpersons: L.M. Ruilope (Spain) and C. Farsang (Hungary)

- 9.00 **Reassessment of ESH guidelines**
J. Redon (Spain)
- 9.20 **Target blood pressure in the elderly**
J.M. Mallion (France)
- 9.40 **The J-curve hypothesis - how to approach it?**
A. Zanchetti (Italy)
- 10.00 **BP variability as a target of antihypertensive treatment**
G. Mancia (Italy)
- 10.20 **General discussion**

10.40 COFFEE BREAK

Session 4

Nebivolol: cardiovascular disease under dual control

supported by an unrestricted educational grant of Menarini International

Chairpersons: E. Agabiti Rosei (Italy) and K. Narkiewicz (Poland)

Lecture

- 11.00 **Vasodilatation and β -3 agonism**
R. Schwinger (Germany)

Lecture

- 11.15 **The role of ischemia in heart failure: new data from Seniors**
G. Ambrosio (Italy)
- 11.30 **Q&A**

Session 5

The hypertensive patient: an ischemic patient

supported by an unrestricted educational grant of Menarini International

Chairpersons: A. Zanchetti (Italy) and T. Meinertz (Germany)

12.00 **Introduction**

A. Zanchetti (Italy)

12.05 **Hypertension and coronary heart disease - a cardiovascular continuum**

G. Filippatos (Greece)

12.30 **A haemodynamically independent agent for a new approach to coronary heart disease**

J. Tamargo (Spain)

12.55 **From trial patients to clinical practice**

M. Komajda (France)

13.20 **Conclusions**

T. Meinertz (Germany)

13.30 LUNCH

Session 6

Problems of antihypertensive treatment: the lercanidipine/enalapril combination

supported by an unrestricted educational grant of Recordati

Chairpersons: G. Mancia (Italy) and S. Erdine (Turkey)

15.00 Introduction

S. Erdine (Turkey)

15.10 Is prevalence of hypertension and other CV factors the same in different population?

A.M. Heagerty (UK)

15.30 Is blood pressure lowering the main objective of antihypertensive treatment?

D. Vinereanu (Romania)

15.50 Fixed combination of CCB-ACEI in hypertensive patients with renal impairment

C. Borghi (Italy)

16.10 Arterial stiffness and hypertension

S. Laurent (France)

16.30 Lercanidipine/enalapril effects on Central Aortic Blood Pressure, Arterial Stiffness (Pulse Wave Velocity and Augmentation Index), Flow Mediated Dilation

S. Taddei (Italy)

16.50 Conclusions

G. Mancia (Italy)

Session 7

New markers of cardiovascular risk

Chairpersons: H. Haller (Germany) and J. Redon (Spain)

17.00 Urinary markers in patients with coronary disease

A. Dominiczak (UK)

17.25 Biomarkers of left ventricular hypertrophy and cardiac fibrosis

J. Diez (Spain)

17.50 Do inflammatory markers predict cardiovascular events?

H. Haller (Germany)

SATURDAY, MARCH 26

Session 8

Arterial function and cardiovascular risk

Chairpersons: R. Cifkova (Czech Republic) and K. Narkiewicz (Poland)

9.00 **Assessment of arterial stiffness in clinical practice**

L. van Bortel (Belgium)

9.20 **Arterial stiffness and cardiovascular prognosis**

A.M. Heagerty (UK)

9.40 **Prevention and treatment of arterial stiffening**

S. Laurent (France)

10.00 **Discussion**

10.15 COFFEE BREAK

Session 9

Comprehensive lipid management for achieving cardiovascular risk reduction

supported by an unrestricted educational grant of Recordati

Chairpersons: J. Chapman (France) and M. Farnier (France)

10.45 **Introduction**

J. Chapman (France)

10.55 **Is the pharmacological profile of pitavastatin different from that of other statins?**

A. Corsini (Italy)

11.15 **From pharmacology to clinical practice - advantages and benefits of pitavastatin**

L. Masana (Spain)

11.35 **Pitavastatin in daily practice**

P. Marquex da Silva (Portugal)

11.55 **Pleiotropic effects of pitavastatin**

J.L. Zamorano (Spain)

12.15 **Effects of statins on atherosclerotic plaques**

J. Chapman (France)

12.35 **Conclusions**

M. Farnier (France)

12.45 LUNCH

Session 10

Meet the Expert - Coronary heart disease: a patient with several conditions

supported by an unrestricted educational grant of Menarini International

Chairpersons: L. Belardinelli (USA) and A. Manolis (Greece)

14.15 **A new treatment approach to coronary heart disease**

L. Belardinelli (USA)

14.30 **A clinical case**

J. Camm (UK)

14.40 **Open debates**

J. Camm (UK)

15.30 **COFFEE BREAK**

Session 11

Discussion sessions for national groups on blood pressure measurements: office, home, ambulatory, central, variability

15.45 - 17.30

Number of sessions to be held in parallel will be decided according to the final size of national groups invited by sponsors.